Abstract
Auto-SCT has been shown to be a potentially curative treatment for a variety of hematological malignancies. Auto-SCT is dependent on the successful mobilization and collection of hematopoietic stem cells to ensure engraftment. The inability to mobilize sufficient number of hematopoietic stem cells using standard cytokine-assisted mobilization strategies excludes eligible patients from potentially curative auto-SCT. Plerixafor (AMD3100; Mozobil), a novel bicyclam antagonist of the SDF-1α/CXCR4 complex, has been reported previously to augment PBSC mobilization in patients undergoing their first planned stem cell mobilization and collection attempt. In our experience, 17 of 20 patients otherwise eligible for auto-SCT who failed previous mobilization attempts had successful mobilization of CD34+ hematopoietic stem cells with one apheresis procedure, and an additional patient required two aphereses procedures, when treated with the combination of plerixafor and G-CSF on a compassionate use protocol available at our institution.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kondo M, Wagers AJ, Manz MG, Prohaska SS, Scherer DC, Beilhack GF et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol 2003; 21: 759–806.
Ng-Cashin J, Shen T . Mobilization of autologous peripheral blood hematopoietic cells for support of high-dose cancer therapy. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas’ Hematopoietic Cell Transplantation, 3rd edn. Blackwell Publishing, Ltd.: Malden, MA, USA, 2004, pp 576–587.
Freuhauf S, Seggewiss R . It's moving day: factors affecting peripheral blood stem mobilization and strategies for improvement. Br J Haematol 2003; 122: 360–372.
Allan DS, Keeney M, Howson-Jan K, Poma J, Weir K, Bhatia M et al. Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 967–972.
Villalon L, Odriozola J, Larana JG, Zamora C, Perez de Oteyza J, Jodra MH et al. Autologous peripheral blood progenitor transplantation with <2 × 106 CD34+/kg: an analysis of variables concerning mobilization and engraftment. Hematol J 2000; 1: 374–381.
Tomblyn M, Burns LJ, Blazar B, Wagner J, Lee C, Rogers T et al. Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma. Bone Marrow Transplant 2007; 40: 111–118.
Oelshlaegel U, Bornhauser M, Boxberger S, Kroschinsky F, Illmer T, Hoelig K et al. Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilization with G-CSF plus AMD3100 in patients with multiple myeloma. Ann Hematol 2007; 86: 569–573.
Hatse S, Princen K, Bridger G, DeClercq E, Schols D . Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002; 527: 262.
Gerlach LO, Skerlj RT, Bridger GJ, Schwartz TW . Molecular interactions of cylcam and bicyclam non-peptide antagonists with CXCR4 chemokine receptor. J Biol Chem 2001; 276: 14153–14160.
Shen H, Cheng T, Olszak I, Garcia-Zepeda E, Lu Z, Herrmann S et al. CXCR-4 desensitization is associated with tissue localization of hemopoietic progenitor cells. J Immunol 2001; 166: 5027–5033.
Link DC . Neutrophil homeostasis: a new role for stromal cell-derived factor-1. Immunol Res 2005; 32: 169–178.
Liesveld JL, Bechelli J, Rosell K, Lu C, Bridger G, Phillips II G et al. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res 2007; 31: 1553–1563.
Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44: 1667–1673.
Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, et al., AMD3100 HIV Study Group. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Accquir Immune Defic Syndr 2004; 37: 1253–1262.
Hubel K, Liles WC, Broxmeyer HE, Rodger E, Wood B, Cooper S et al. Leukocytosis and mobilization of CD34+ hematopoietic progenitor by AMD3100, a CXCR4 antagonist. Support Cancer Ther 2004; 1: 165–172.
Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728–2730.
Broxmeyer HE, Hangoc G, Cooper S, Campbell T, Ito S, Mantel C . AMD3100 and CD26 modulate mobilization, engraftment, and survival of hematopoietic stem and progenitor cells mediated by the SDF-1/CXCL12-CXCR4 axis. Ann N Y Acad Sci 2007; 1106: 1–19.
Liles WC, Rodger E, Broxmeyer HE, Dehner C, Badel K, Calandra G et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with G-CSF by single dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005; 45: 295–300.
Flomenberg N, Devine SM, DiPersio JF, Liesveld JL, McCarty JM, Rowley SD et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867–1874.
Cashen AF, Lazarus HM, Devine SM . Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF? Bone Marrow Transplant 2007; 39: 577–588.
Flomenberg N, Dipersio J, Calandra G . Role of CXR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells. Acta Haematologica 2005; 114: 198–205.
Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1095–1102.
Flomenberg N, DiPersio J, Liesveld J, McCarty J, Rowley S, Vesole D et al. AMD3100+G-CSF hematopoietic progenitor cell (HPC) mobilization is safe, effective, and superior to mobilization with G-CSF alone. [oral session] American Society of Hematology: San Diego, CA, USA, 2003.
Holtan SG, Porrata LF, Micallef IN, Padley DJ, Inwards DJ, Ansell SA et al. AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. Clin Lymphoma Myeloma 2007; 7: 315–318.
Dugan MJ, Akard LP, Thompson JM, Nademanee A, Maziarz RT, Bensinger WI et al. Treatment with AMD3100 in multiple myeloma or non-Hodgkin's lymphoma patients to increase the number of peripheral blood stem cells when given with a mobilizing regimen of chemotherapy and G-CSF. [poster P 503] Annual Meeting of the European Group for Blood and Marrow Transplantation 31st 2005 (submitted).
Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Flomenberg N, Weisdorf D et al. AMD3100 plus G-CSF rapidly mobilizes hematopoietic progenitor cells in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM), including those traditionally considered poor mobilizers. [abstract 271] Tandem BMT Meeting: Keystone, CO, USA, 2005.
Roberts CH, Chung HM, Candler KS, Calandra G, Badel K, McCarty JM . Single-center experience with the early use of AMD3100 plus G-CSF for mobilization of hematopoietic progenitor cells in patients classified as poor mobilizers. [abstract 99] Tandem BMT Meeting: Keystone, CO, USA, 2007.
Calandra G, McCarty J, McGuirk J, Barlogie B, Crocker S-A, Badel K . AMD3100 plus G-CSF mobilizes the majority of non-Hodgkin’s lymphoma (NHL), multiple myeloma (MM), and Hodgkin’s disease (HD) patients who failed prior mobilization with other regimens. Bone Marrow Transplant 2008; 41: 331–338.
Maziarz RT, Dunn A, Hansen L, Hansen K, Leis JF, Hayes-Lattin B et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and AMD3100: an institutional experience. [abstract 5460] American Society of Hematology: Orlando, FL, USA, 2006.
DiPersio J, Stadtmauer EA, Nademanee AP, Stiff P, Micallef I, Angell J et al. A phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (plerixfor)+G-CSF vs G-CSF+placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation. [abstract 445] American Society of Hematology: Atlanta, GA, USA, 2007.
DiPersio J, Micallef I, Stiff P, Bolwell B, Maziarz RT, Angell J et al. A phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (plerixfor)+G-CSF vs G-CSF+placebo for mobilization in non-Hodgkin's lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. [abstract 601] American Society of Hematology: Atlanta, GA, USA, 2007.
Stroncek DF, Clay ME, Petzoldt ML, Smith J, Jaszcz W, Oldham FB et al. Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion 1996; 36: 585–589.
Dermirer T, Buckner CD, Gooley T, Appelbaum FR, Rowley S, Chauncey T et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 937–941.
Haas R, Murea S . The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells. Cytokines Mol Ther 1995; 1: 249–270.
Amgen Inc.. Nupogen. Physician's Desk Reference, 60th edn. Thomson PDR: Montvale, NJ, USA, 2006, pp 598–603.
Acknowledgements
We thank Binnie Grant and the late Dan Callaway for their assistance in data management of patients on this protocol.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fowler, C., Dunn, A., Hayes-Lattin, B. et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant 43, 909–917 (2009). https://doi.org/10.1038/bmt.2008.409
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.409
Keywords
This article is cited by
-
Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study
Bone Marrow Transplantation (2016)
-
Identification of a New Cell Population Constitutively Circulating in Healthy Conditions and Endowed with a Homing Ability Toward Injured Sites
Scientific Reports (2015)
-
Efficacy of plerixafor in children with malignant tumors failing to mobilize a sufficient number of hematopoietic progenitors with G-CSF
Bone Marrow Transplantation (2015)
-
Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients
Blood Cancer Journal (2014)
-
Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma
Bone Marrow Transplantation (2014)